There are alternative medications to Ixazomib, such as bortezomib. Ixazomib is a reversible proteasome inhibitor that can be used in combination with dexamethasone and lenalidomide to treat adult patients with multiple myeloma who have received at least one prior therapy. It is contraindicated in patients who are hypersensitive to the active ingredient or any excipients of the product. Contraindications to the use of dexamethasone and lenalidomide in combination with dexamethasone and lenalidomide should also be referred to the contraindications to the combination of the drugs. Adverse reactions such as thrombocytopenia, diarrhea, constipation, nausea, vomiting, peripheral neuropathy, rash, and edema may occur with the use of Ixazomib. A similar drug to Ixazomib is bortezomib, which has a similar mechanism of action, but bortezomib needs to be administered by injection, while Ixazomib is administered orally. Moreover, there are some differences between bortezomib and Ixazomib in terms of drugs used in combination and contraindications during bortezomib treatment. Bortezomib is used in combination with melphalan and prednisone for the treatment of previously untreated multiple myeloma that is not amenable to bone marrow transplantation and high-dose chemotherapy, or as a single agent for the treatment of multiple myeloma that has relapsed after receiving at least one or more therapies; and is contraindicated in patients who are allergic to bortezomib, boron, or mannitol. Adverse reactions such as diarrhea, nausea, and peripheral neuropathy may occur with use of the drug. Patients who need to use Ixazomib or need to use other drugs to replace Ixazomib treatment should be under the supervision of a doctor.